New combo pill for high blood pressure enters first human tests
NCT ID NCT07421414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new combination pill containing two blood pressure medicines (fimasartan and indapamide) in 48 healthy adults. The study compares the combined pill to taking each drug separately, measuring how the body absorbs the drugs and checking for side effects. It is a Phase 1 study, so it focuses on safety and drug levels, not on treating high blood pressure yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fimasartan and Indapamide (a combination pill)
What this could lead to
If successful, this could lead to a simpler once-daily pill for high blood pressure, potentially improving patient adherence.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only checks drug levels and safety, not whether the combo actually controls blood pressure. Many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••